Traduction de «since its first » (Néerlandais → Français) :

TERMINOLOGIE

first-pass | eerste hindernis
?

TRADUCTIONS EN CONTEXTE

Exelon/Exelon Patch (USD 251 million, +17% cc) has been driven by Exelon Patch since its first launch in 2007, generating more than 60% of total Exelon sales in the first quarter of 2010 compared to 46% in the 2009 period.
Exelon/Exelon Patch (USD 251 millions, +17% tcc) a été emmené par Exelon Patch depuis son lancement initial en 2007, engendrant plus de 60% du chiffre d’affaires total d’Exelon au premier trimestre 2010 comparé à 46% à la même période de 2009.

Exforge, a single-pill combination of Diovan (valsartan) and the calcium channel blocker amlodipine, has been consistently setting new standards for high blood pressure combination therapies since its first launch in 2007.
Exforge, un comprimé associant Diovan (valsartan) et l’amlodipine, un inhibiteur des canaux calciques, n’a cessé d’établir, depuis son premier lancement en 2007, de nouvelles normes dans le domaine des médicaments combinés pour traiter l’hypertension.

Consumer Health: USD 1.5 billion (0%, +5% lc) All businesses contributed to the strongest underlying quarterly performance since the first quarter of 2008.
Consumer Health: USD 1,5 milliard (0%, +5% en m. l).

Lucentis (USD 886 million, +122% lc), a biotechnology eye therapy now approved in more than 70 countries, has delivered dynamic growth since its first European launch in early 2007.
Lucentis (USD 886 millions, +122% en m. l.), traitement oculaire biotechnologique disponible dans plus de 70 pays, a connu une croissance vigoureuse depuis son premier lancement en Europe début 2007.

Onbrez Breezhaler (USD 5 million) has demonstrated strong performance following EU approval and since first launching in late 2009 in Germany for adult patients with chronic obstructive pulmonary disease (COPD).
Onbrez Breezhaler (USD 5 millions) a réalisé une excellente performance à la suite de son homologation dans l’UE et depuis son premier lancement à fin 2009 en Allemagne pour le traitement des adultes souffrant de broncho-pneumopathie chronique obstructive (BPCO).

haemovigilance data and monitoring their implementation ●● The first annual report of the Haemovigilance Centre was published in 2007 Since November 2005, hospitals and blood establishments have been required to report to the Belgian Centre for Haemovigilance of the FAMHP serious reactions during the collection or administration of blood components and serious events relating to the quality or safety of blood components.
haemovigilance data and monitoring their implementation ●● The first annual report of the Haemovigilance Centre was published in 2007 Since November 2005, hospitals and blood establishments have been required to report to the Belgian Centre for Haemovigilance of the FAMHP serious reactions during the collection or administration of blood components and serious events relating to the quality or safety of blood components.

Galvus/Eucreas (USD 181 million, +327% lc), oral treatments for type 2 diabetes, have achieved rapid success in many European, Latin American and Asia-Pacific markets since first launched in 2007.
Galvus/Eucreas (USD 181 millions, +327% en m. l.), traitements par voie orale du diabète de type 2, ont très vite rencontré le succès dans de nombreux marchés d'Europe, d'Amérique latine et d'Asie-Pacifique depuis leur premier lancement en 2007.

Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.